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Since the outbreak of SARS-CoV-2, also known as COVID-19, conflicting theories
have circulated on the influence of angiotensin-converting enzyme inhibitors (ACEi)
and angiotensin II receptor blockers (ARB) on incidence and clinical course of
COVID-19, but data are scarce. The COvid MEdicaTion (COMET) study is an
observational, multinational study that focused on the clinical course of COVID-19
(i.e. hospital mortality and intensive care unit [ICU] admission), and included
COVID-19 patients who were registered at the emergency department or admitted
to clinical wards of 63 participating hospitals. Pharmacists, clinical pharmacologists or
treating physicians collected data on medication prescribed prior to admission. The
association between the medication and composite clinical endpoint, including
mortality and ICU admission, was analysed by multivariable logistic regression models
to adjust for potential confounders. A total of 4870 patients were enrolled. ACEi
were used by 847 (17.4%) patients and ARB by 761 (15.6%) patients. No significant
association was seen with ACEi and the composite endpoint (adjusted odds ratio
[OR] 0.94; 95% confidence interval [CI] 0.79 to 1.12), mortality (OR 1.03; 95%CI 0.84
to 1.27) or ICU admission (OR 0.96; 95%CI 0.78 to 1.19) after adjustment for
covariates. Similarly, no association was observed between ARB and the composite
endpoint (OR 1.09; 95%CI 0.90 to 1.30), mortality (OR 1.12; OR 0.90 to 1.39) or ICU
admission (OR 1.21; 95%CI 0.98 to 1.49). In conclusion, we found no evidence of a
harmful or beneficial effect of ACEi or ARB use prior to hospital admission on ICU
admission or hospital mortality.
Principal investigator: For this study there was no principal investigator who carried direct clinical responsibility for patients. Local COMET study investigators collected pseudonymized data in
their respective centres.
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1 | INTRODUCTION
The severe acute respiratory syndrome (SARS)-coronavirus 2 (CoV-2)
is responsible for coronavirus disease 2019 (COVID-19). SARS-CoV-2
invades human cells by binding a viral spike protein to angiotensin
converting enzyme (ACE) 2, similar to SARS-CoV-1 which caused an
earlier outbreak of SARS in 2002.1–4 Renin–angiotensin–aldosterone
system (RAAS) activation ensures conversion of angiotensin I to
angiotensin II by ACE1. Activating the type I angiotensin II (AT1)
receptor causes vasoconstriction, inflammation and fibrosis, whereas
conversion of angiotensin I and II by ACE2 leads to a pathway involv-
ing angiotensin-(1–9) and angiotensin-(1–7), which is thought to coun-
ter these detrimental effects (Figure 1A). The binding of SARS-CoV-2
and ACE2 leads to local downregulation of ACE2.5 In turn, angiotensin
II accumulates resulting in increased vascular permeability and an
acute respiratory distress syndrome-like syndrome. In addition to its
role in RAAS modulation, ACE2 is also involved in degrading several
other substrates, such as apelin and bradykinin. Recently, its role in
degrading bradykinin has been suggested to play a causal role in the
development of severe acute respiratory distress syndrome.6 Previous
studies showed that during lung injury, ACE1, angiotensin II, and the
AT1 receptor function as lung injury-promoting factors, whereas
ACE2 protects against lung injury.5,7 Since RAAS inhibitors (RAASi),
such as ACE(1) inhibitors (ACEi) or angiotensin II receptor blockers
(ARB), have been described to have an effect on ACE2 expression
(i.e. upregulation in various organs), these drugs may increase the risk
of infectivity of SARS-CoV-2 resulting in a higher incidence of
COVID-19 in patients using RAASi (Figure 1B).8 The theoretical
increased risk of infectivity has been strengthened by literature show-
ing that conditions in which RAASi are used, such as hypertension,
diabetes mellitus and cardiovascular diseases, correlate with COVID-
19-related mortality.8–11 Paradoxically, beneficial effects have also
been suggested, since an increase in ACE2, if truly present, might
protect against inflammation and lung injury as described earlier
(Figure 1B).12–14 In the absence of evidence, randomized clinical trials
have been initiated in which ACEi and ARB have been either
discontinued or prescribed.15–18 The COMET study aims to evaluate
the effect of ACEi and ARB use prior to hospital admission on
COVID-19-related outcomes (e.g. mortality and ICU admission).
2 | METHODS AND ANALYSIS
2.1 | Study design and participants
The COvid MEdicaTion (COMET) study, is a European, multinational,
multicentre, retrospective study. The rationale and design have
previously been described in detail.19 In summary, patients were
included by pharmacists, clinical pharmacologists, or treating physi-
cians from 63 hospitals in 10 countries. To prevent major selection
bias, a minimum number of patients was set to participate in the
study (i.e. 50 patients per centre or all patients if <50 patients were
available). All participating investigators were requested to consecu-
tively include either those patients who were SARS-CoV-2 positive
registered at the Emergency Department (42% of participating hos-
pitals) or on the clinical wards (58% of participating centres). The
major criterion for a patient to be included in the study was
COVID-19 positive by either a positive SARS-CoV-2 polymerase
chain reaction (PCR) or a high clinical likelihood based on bilateral
pulmonary infiltrates not explained otherwise after consensus by
the local COVID-19 expert team, based on clinical, biochemical and
radiological criteria. The timeframe of inclusion of consecutive
patients was at the discretion of the participating hospital and
inclusion was performed during a median of 25 days (interquartile
range [IQR] 15–45).
2.2 | Data collection
The timeframe for data collection was limited as it took place
during the first wave of COVID-19 infections. Data collection
focused on prescribed medication prior to admission, patient and
admission characteristics, and clinical outcomes (e.g. hospital
mortality and ICU admission). The current analysis focused on the
use of RAASi (ACEi or ARB) prior to admission and clinical out-
comes. The following variables were collected: year of birth, sex,
What is already known about this subject
• Several studies have shown that the use of renin–angio-
tensin–aldosterone system inhibitors (RAASi) was not
associated with a more serious course or higher mortality
of COVID-19 patients compared to no use of RAASi.
What this study adds
• A large multicentre, international cohort that further con-
firms the results shown in previously published studies.
• In addition to mortality, there is no association between
the use of preadmission RAASi and intensive care unit
admission in COVID-19 patients.
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prescribed medication by ATC code, dosing regimen, hospital
mortality and ICU admission. As the entry of comorbid disease is
time consuming and often incomplete, data on type of drugs
served as a proxy for disease; hypertension, atherosclerotic cardio-
vascular disease (i.e. coronary artery disease, cerebrovascular
disease, or peripheral artery occlusive disease)and diabetes mellitus.
These conditions were considered present in patients when any
blood pressure-lowering drugs, antiplatelet drugs, or glucose-
lowering drugs or insulins were used, respectively.
Medication in single pill combinations were coded into the
individual drug classes (e.g. if a patient used a combination of both an
ACEi and a beta blockers, they were included as using an ACEi and a
β-blocker).
In reference to the Bradford Hill criteria of causality,20 an explor-
atory analysis was added to assess dose response relationship on the
clinical course. Each daily dose of ACEi and ARB was proportionally
converted to a standard dose. The standard dose is an equipotent
daily dose within a drug class and was based on the usual mainte-
nance dose of each drug recommended in reference pharmacopoeias.
The standard dose has been suggested to describe equipotency better
than the World Health Organization daily defined dose.21 For
example, lisinopril 20 mg was considered equivalent to 2 standard
doses ACEi.
Data were collected in an online database (Clinical Rules reporter,
version 1.6.3, Digitalis Rx, Amsterdam, the Netherlands). A study
number was assigned to each participant. The coding file was only
available to the local investigator. Each local investigator collected
pseudonymized data. The institutional review committee of the
main site, Erasmus MC in the Netherlands, approved the study
(MEC-2020-0277), as well each institutional review board of the
participating hospitals approved the use of data, as described in our
protocol study.19 All data were treated according to the privacy
regulations applicable for European countries and conducted in
accordance with the Declaration of Helsinki.22
2.3 | Study endpoints
The study endpoints were a composite of clinical course of the
COVID-19 patients including mortality and ICU admission, and both
mortality and ICU admission as individual endpoints. Both mortality
and ICU admission were in-hospital endpoints and scored according
to the patient records.
2.4 | Statistical analysis
Descriptive statistics were used to depict the characteristics of
patients in the total study sample, and stratified for patients with-
out RAASi, ACEi use and ARB use. All characteristics were
described as counts (%) and medians [IQR]. Patients without RAASi
were used as the reference category. For the study endpoints, a
multivariable binary logistic regression model was used to analyse
the data. Results were presented as odds ratios (OR) with
corresponding 95%confidence interval (95%CI). First, crude,
unadjusted estimates were obtained (Model I). These were then
F IGURE 1 Schematic illustration of the renin–angiotensin–aldosterone system including the role of ACE2 and link with SARS-CoV-2
infection. (A) ACE2 converts angiotensin II to Ang (1–7) and angiotensin I to Ang (1–9). Ang (1–7) and Ang (1–9) have an organic-protective effect
and counterbalance the negative effects of binding AT1R by angiotensin II. (B) Binding of SARS-CoV-2 on ACE2 internalize the virus into the cell.
ACE2 may be upregulated by renin–angiotensin–aldosterone system inhibitor, leading to the hypothesis that the infectivity of SARS-CoV-2
increases. However, due to the beneficial effects shown in (A), this increase in ACE2 might also be beneficial due to protection against
inflammation and lung injury in conditions known for low ACE2 expression, such as diabetes and hypertension. Abbreviations: ACE, angiotensin
converting enzyme; ACEi, ACE inhibitor; Ang, angiotensin; ARB, angiotensin receptor blocker; AT1R, type 1 angiotensin II receptor, AT2R; type
2 angiotensin II receptor; MasR, Mas receptor
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adjusted for age and sex (Model II), and finally for the concomitant
blood pressure-lowering drugs other than RAASi, antiplatelet drugs
and glucose-lowering drugs. (Model III). In addition, an exploratory
model with adjustment for a propensity score (PS) of RAASi, ACEi
or ARB use was developed (Model IV). The use of propensity
scores was employed as a method for dealing with confounding
factors.23 The propensity score was defined as an individual's prob-
ability of being treated with the drug of interest given the vari-
ables of that individual. Thus, the use of a probability that a
subject would have been treated allows adjustment of the esti-
mated treatment effect, creating quasirandomized trial and reducing
confounding by indication.24 The PS was derived from a logistic
regression model with either RAASi, ACEi or ARB as dependent
variables, and clinical factors as potential determinants. The individ-
ual models have been displayed in the manuscript to identify the
effect of correcting for the additional potential confounding fac-
tors. Effect modification was assessed for age and sex by adding a
multiplicative variable. The data showed no multiplicative effect
modification for RAASi, ACEi or ARB.
A potential effect of RAAS modulation on clinical endpoints may
be offset by comorbidity such as hypertension. To explore the latter,
additional analyses were performed with calcium-channel blockers
(CCB). Patients without CCB were used as the reference category.
The association with these drugs and clinical endpoint were added as
CCB do not target RAAS.
There was missing data for mortality in 152 patients (3.1%) and
for ICU admission in 156 patients (3.2%). Imputation of missing data
in some variables such as body mass index or clinical endpoints was
not applied due to potential collinearity and to the limited number of
available variables.
A 2-tailed probability value of <.05 was used as the criterion for
statistical significance. All analyses were performed using SPSS,
version 25.0 on Windows (SPSS inc., Chicago, IL, USA).
3 | RESULTS
3.1 | Demographics and characteristics
A total of 4870 patients with COVID-19 were included. Table 1
describes the baseline characteristics. The median age was 68 [IQR
57–78] and 62.5% of the patients were male. Prior to admission,
a RAASi was used by 1592 patients (32.7%), an ACEi by
847 (17.4%) patients and an ARB by 761 (15.6%) patients. In total
1206 (24.8%) patients were admitted to the ICU, and 975 (21.0%)
patients died.
Table 2 describes the difference in baseline characteristics
between patients without RAASi and patients with an ACEi or ARB
prior to admission. Patients with RAASi are generally older (Agemedian
ACEi 73 y [IQR 64–80], Agemedian ARB 73 y [IQR 66–80] compared to
no RAASi use (Agemedian no RAASi 65 [IQR 54–76]), used more other
blood pressure-lowering drugs (ACEi 76.5%, ARB 80.2% vs. no RAASi
29.5%) and used overall more drugs (drugsmedian ACEi and ARB both
7 [IQR 5–10] vs. drugsmedian no RAASi 3 [IQR 1–6].
3.2 | Clinical outcomes and used medication
The association between RAASi and the study endpoints is displayed
in Table 3. After adjustment for available confounders (Model III), no
TABLE 1 Baseline characteristics
Total
(n = 4870)




Male sex 3046 (62.5)
Concomitant medication
Blood pressure-lowering medication 2560 (52.6)
RAASi 1592 (32.7)
Angiotensin-converting enzyme inhibitors 847 (17.4)
Angiotensin receptor blocker 761 (15.6)
Blood pressure-lowering medication (excluding RAASi) 2213 (45.4)
Calcium-channel blocker 883 (18.1)
Diuretic 905 (18.6)
Potassium-sparing diuretic 159 (3.3)
Beta-blocker 1219 (25.0)
Antiplatelet therapy 1025 (21.0)
Glucose lowering medication 983 (21.2)














Composite clinical endpoint 1873 (38.5)
Mortality 975 (21.0)
Intensive care unit admission 1206 (24.8)
Displayed values are medium [interquartile range] or n (%).
RAASi, renin–angiotensin–aldosterone system inhibitors.
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TABLE 2 Characteristics per exposure
No RAASi (n = 3278) ACEi (n = 847) ARB (n = 761)
Age (y) 65 [54–76] 73 [64–80] 73 [66–80]
<65 1627 (49.6) 220 (26.0) 177 (23.3)
65–75 750 (22.9) 243 (28.7) 247 (32.5)
>75 901 (27.5) 384 (45.3) 337 (44.3)
Male sex 2023 (61.7) 587 (69.3) 447 (58.7)
Concomitant medication
Blood pressure-lowering medication (excluding RAASi) 968 (29.5) 648 (76.5) 610 (80.2)
Calcium-channel blocker 361 (11.0) 259 (30.6) 267 (35.1)
Diuretic 383 (11.7) 270 (31.9) 256 (33.6)
Potassium-sparing diuretic 64 (2.0) 49 (5.8) 46 (6.0)
Beta-blocker 572 (17.4) 353 (41.7) 299 (39.3)
Antiplatelet therapy 467 (14.2) 317 (37.4) 243 (31.9)
Glucose lowering drugs 457 (13.9) 275 (32.5) 259 (34.0)
Number of unique drugs 3 [1–6] 7 [5–10] 7 [5–10]
Endpoints
Composite clinical endpoint 1200 (36.6) 346 (40.9) 333 (43.8)
Mortality 556 (17.0) 218 (25.7) 205 (26.9)
Intensive care unit admission 828 (25.3) 187 (22.1) 194 (25.5)
Displayed values are medium [interquartile range] or n (%).
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; RAASi, renin–angiotensin–aldosterone system inhibitor.
TABLE 3 Association between RAAS inhibition and clinical outcomes
Study endpoint No RAASi (n = 3278)
RAASi (n = 1592) ACEi (n = 847) ARB (n = 761)
OR (95%CI) OR (95%CI) OR (95%CI)
Composite clinical endpoint (mortality and/or ICU admission) (n = 1873)
I REF 1.28 (1.13–1.45) 1.21 (1.04–1.42) 1.35 (1.15–1.59)
II 1.10 (0.97–1.25) 1.02 (0.86–1.20) 1.18 (1.00–1.40)
III 1.01 (0.87–1.16) 0.94 (0.79–1.12) 1.09 (0.90–1.30)
IV 1.01 (0.88–1.17) 0.95 (0.80–1.13) 1.10 (0.92–1.32)
Mortality (n = 975)
I REF 1.77 (1.53–2.05) 1.72 (1.43–2.06) 1.83 (1.52–2.20)
II 1.22 (1.04–1.43) 1.16 (0.95–1.41) 1.29 (1.05–1.57)
III 1.07 (0.90–1.27) 1.03 (0.84–1.27) 1.12 (0.90–1.39)
IV 1.08 (0.92–1.28) 1.03 (0.84–1.27) 1.14 (0.93–1.41)
ICU admission (n = 1206)
I REF 0.93 (0.80–1.06) 0.85 (0.70–1.01) 1.01 (0.84–1.22)
II 1.03 (0.89–1.20) 0.92 (0.76–1.12) 1.15 (0.95–1.39)
III 1.06 (0.90–1.26) 0.96 (0.78–1.19) 1.21 (0.98–1.49)
IV 1.06 (0.90–1.25) 0.96 (0.79–1.18) 1.20 (0.98–1.48)
Model: I, crude; II, adjusted for sex, age category (<65 y, 65 to 75 y, >75 y); III, II + additional adjustment for concomitant drugs (blood pressure-lowering
drugs other than RAASi, antiplatelet drugs, glucose lowering drugs); IV, adjusted for the propensity score, composed of sex, age category, concomitant
drugs.
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CI, confidence interval; ICU, intensive care unit; OR, odds ratio; RAASi,
renin–angiotensin–aldosterone system inhibitor.
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statistically significant association of RAASi use on the composite
clinical endpoint (ORRAASi: 1.01; 95%CI: 0.87 to 1.16), mortality
(ORRAASi: 1.07; 95%CI: 0.90 to 1.27) or ICU admission (ORRAASi: 1.06;
95%CI: 0.90 to 1.26) was present when compared to no RAASi use
prior to admission. Similar results were seen for ACEi and ARB's after
adjustment for available confounders (Model III) on the composite
clinical endpoint (ORACEi: 0.94; 95%CI: 0.79 to 1.12 and ORARB: 1.09;
95%CI: 0.90 to 1.30), mortality (ORACEi: 1.03; 95%CI: 0.84 to 1.27
and ORARB: 1.12; 95%CI: 0.90 to 1.39) or ICU admission (ORACEi:
0.96; 95%CI: 0.78 to 1.19 and ORARB: 1.21, 95%CI: 0.98 to 1.49)
when compared to no RAASi use prior to admission. Similar to Model
III, no statistically significant association was seen for RAASi, ACEi or
ARB and the composite clinical endpoint, mortality and ICU admission
when compared to no RAASi prior to admission after adjusting for the
propensity score (model IV).
The exploratory analyses with CCBs showed similar results for
mortality (model III ORCCB: 1.12; 95%CI: 0.92 to 1.35). However, a
statistically significant association was seen between CCB use and
ICU admission (ORCCB 1.28; 95% CI: 1.07 to 1.54) when compared to
no CCB use prior to admission (Table S1).
3.3 | Clinical outcomes and standard dose of
medication
The association between the standard dose of medication and clinical
outcome is displayed in Table 4. Similar to the (binary) use of RAASi,
ACEi and ARB, there was no statistically significant association
between the dose of RAASi, ACEi or ARB and the composite clinical
endpoint, mortality or ICU admission.
4 | DISCUSSION
This multinational, multicentre, retrospective cohort study aimed to
investigate the associations between the use of RAASi, ACEi and ARB
prior to admission, and hospital mortality and ICU admission in a large
sample of COVID-19 patients. The results indicated that the use of
RAASi prior to hospital admission had neither a harmful, nor beneficial
effect on mortality or ICU admission. Additionally, no differential
effect was observed when using an ACEi or ARB prior to admission
on clinical outcomes.
Since the outbreak of COVID-19, concerns have emerged about
the effect of different types of medication on clinical course and
mortality of COVID-19, with a particular focus on ACEi and ARB.
Recently, the first studies addressing this subject have been published,
all with different study designs.25–30 Previous studies assessed both
the effect of RAASi on the incidence of COVID-1925,26,30 and the
effect of the use of RAASi prior to admission on clinical outcomes of
COVID-19.27–29 These studies found no relationship of RAASi on
either the incidence or COVID-19 related morbidity or mortality. One
of the first retrospective studies by Mehra et al.31 included 8910
patients from 169 hospitals in 11 countries and examined the rela-
tionships between many variables and in-hospital mortality without a
pre-specified hypothesis increasing the probability of chance associa-
tions. Remarkably, this study was withdrawn due to concerns about
study design and data, because all the authors were not granted
access to the raw data and the raw data could not be made available
to a third-party auditor.32 As a result, the primary data sources under-
lying this article were unable to be validated.33 This emphasizes the
importance of replication studies, preferably with different study
designs since every study design has its own bias.
TABLE 4 Association between standard dose of RAAS inhibition and clinical outcomes
Study endpoint No RAASi (n = 3278)
RAASi (n = 1592) ACEi (n = 847) ARB (n = 761)
OR (95%CI) OR (95%CI) OR (95%CI)
Composite clinical endpoint (mortality and/or ICU admission) (n = 1873)
I REF 1.05 (1.02–1.08) 1.05 (1.01–1.09) 1.05 (1.00–1.09)
II 1.02 (0.99–1.05) 1.02 (0.98–1.06) 1.01 (0.97–1.06)
III 1.01 (0.98–1.04) 1.01 (0.97–1.05) 1.00 (0.95–1.04)
Mortality (n = 975)
I REF 1.09 (1.05–1.12) 1.09 (1.04–1.13) 1.11 (1.06–1.16)
II 1.02 (0.99–1.06) 1.02 (0.97–1.06) 1.04 (0.99–1.09)
III 1.00 (0.97–1.04) 1.00 (0.95–1.05) 1.01 (0.96–1.06)
ICU admission (n = 1206)
I REF 0.98 (0.95–1.01) 0.99 (0.94–1.03) 0.97 (0.92–1.02)
II 1.00 (0.96–1.03) 1.01 (0.96–1.05) 0.99 (0.93–1.04)
III 1.00 (0.96–1.04) 1.01 (0.96–1.06) 0.99 (0.93–1.04)
*OR per 1 standard dosing increase (e.g. lisinopril 10–20 mg).
Model: I, crude; II, adjusted for sex, age category (<65 y, 65 to 75 y, >75 y); III, II + additional adjustment for concomitant drugs (blood pressure-lowering
drugs other than RAASi, antiplatelet drugs, glucose lowering drugs).
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CI, confidence interval; ICU, intensive care unit; OR, odds ratio; RAASi,
renin–angiotensin–aldosterone system inhibitor.
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In the studies of Mancia et al.25 and Reynolds et al.,26 data were
collected from a general database (in Mancia et al. up to date up to
December 2019) and electronic health records respectively to assess
the incidence of COVID-19 in RAASi users. In contrast, the study of
Abajo et al.30 used a case–control design. A strength of the COMET
study design is that hospital pharmacists, clinical pharmacologists and
treating physicians obtained and verified real-time medication data,
resulting in critically reviewed, up-to-date data.
Zhang et al.27 and Li et al.28 assessed the association between
RAASi use and all-cause mortality and severe diseases outcomes
respectively. They did not perform a differential analysis on the effect
of ACEi or ARB on the COVID-19-related morbidity and mortality.
The present study examined both the effect of ACEi and ARBs
separately as well as RAASi in general on the clinical course and
mortality of COVID-19. Furthermore, the effect of CCB on the clinical
course and mortality of COVID-19 was assessed. This served as a
confirmation, since CCBs have a blood pressure lowering effect, but
do not target the RAAS. Additionally, a dose–response analysis of
ACEi and ARBs in relation to clinical course and outcome was
performed, had an association been discovered this would have been
used to assess causality.
A statistically significant effect for the use of CCBs prior to
admission and trend for the use of ARB was observed on admis-
sion to ICU. This might be due to confounding or multiple testing.
However, the increased risk of ICU admission could also be related
to the underlying hypertensive condition. Although RAASi are
mostly prescribed for their blood pressure-lowering effects, RAASi
is the therapy of choice in other morbidities, such as congestive
heart failure. However, the low percentage of users of potassium-
sparing diuretics suggests that the percentage with clinically
relevant congestive heart failure was low and this might not have
significantly affected the correlation between RAASi and clinical
course of COVID-19.
In contrast to more regionally centred studies, the COMET study
included patients from 63 hospitals from 10 European countries,
including both academic and nonacademic hospitals. This makes the
data collected broadly representative and generalizable.
Finally, the protocol was published for scientific transparency.19
A potential limitation of the current study, similarly to the earlier
studies, was the potential for confounding due to the observational
design. Confounding by indication is important in intervention-related
studies. To correct for this, a PS was calculated and the association
between RAAS inhibition and clinical outcomes was assessed using an
exploratory PS model. A PS was created and several variables were
adjusted for; however, due to the limited number of collected
variables, the PS may have limited value. The minimization of
collected parameters ensured quick data entry and made participating
in this study accessible, but the limited number of parameters
precluded extensive correction for potential confounders. Nonethe-
less, due to detailed medication data collected, major comorbidities
could be inferred and included in the multivariate and PS analyses.
Secondly participants in our study were hospitalized patients. Patients
with relatively mild disease who were not admitted were not included.
The inclusion of patients was consecutive, thereby limiting major
selection bias. However, this design limits the generalizability of the
results to patients in primary health care.
The high incidence of RAASi is in line with the high frequency
of RAASi use in the Netherlands, this can be explained by the fact
that the Dutch centres were large contributors to this study.
Similar percentages are seen in other studies. Mancia et al.25
reported 23.9% ACEi users and 22.2% ARB users in COVID-19
positive patients. Additionally, Conversano et al.29 reported a 32%
use of ACE/ARB in survivors who tested positive for COVID-19.
The large proportion of elderly patients with comorbidities also
contributes to the high incidence of RAASi in COVID-19 patients,
which is supported by our data. The data collection regarding med-
ication in the current study focused on data prior to hospital
admission. No information on medication continuation or discontin-
uation after testing positive for COVID-19 was available. If RAASi
was discontinued during hospitalization, it is unlikely to produce
different outcomes concerning the effect of ACE2 on our end-
points. As seen in other RAAS parameters, up- and downregulation
of ACE2 might take time and would not have an immediate effect.
Furthermore, clinical guidelines and statements recommended
continuation of RAASi.34–36 Nonetheless, continued RAASi during
hospitalization could be an aim of a follow-up study. Furthermore,
we have no insight into adherence to treatment. All data presented
are prescribed medication. However, this applies to almost all
studies in this area and nonadherence would probably result in
nondifferential misclassification.
In conclusion, the COMET study showed that RAASi use prior to
hospital admission was not associated with an increase in COVID-19
related mortality or ICU admission. The results indicated that the
preadmission use of RAASi has neither a harmful nor beneficial effect
on hospital mortality or ICU admission. The data do not suggest that
the relationship between hypertension and severity of COVID-19 can
be explained by the use of ACEi or ARB prior to hospital admission
and their regulation of ACE2.
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